Strides Arcolab soars on receiving USFDA approval for Methoxsalen Softgel Capsules

06 Jun 2014 Evaluate

Strides Arcolab is currently trading at Rs. 582.95, up by 35.50 points or 6.48% from its previous closing of Rs. 547.45 on the BSE.

The scrip opened at Rs. 552.55 and has touched a high and low of Rs. 583.00 and Rs. 550.00 respectively. So far 72396 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 583.00 on 06-Jun-2014 and a 52 week low of Rs. 333.22 on 01-Aug-2013.

Last one week high and low of the scrip stood at Rs. 583.00 and Rs. 502.25 respectively. The current market cap of the company is Rs. 3282.07 crore.

The promoters holding in the company stood at 27.67% while Institutions and Non-Institutions held 51.95% and 20.38% respectively.

Strides Arcolab has received approval from the United States Food & Drug Administration (USFDA) for Methoxsalen Capsules USP, 10 mg (Soft Gelatin Capsules). According to IMS data, the US market for generic Methoxsalen Capsule is approximately $13.6 Million, with no generic player. The product will be manufactured at the Company's USFDA approved Oral dosage facility at Bangalore and marketed directly by Strides in the US Market.

Strides Arcolab is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.

 

Strides Pharma Scien Share Price

875.35 46.70 (5.64%)
15-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1528.20
Dr. Reddys Lab 5872.35
Cipla 1405.95
Zydus Lifesciences 997.45
Lupin 1638.40
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.